The university, which helped develop the Astrazeneca Vaccine has acknowledged fears over a potential link to clots, saying it would await additional data from Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) before restarting the study.
In a statement it said that there were no safety concerns in the trial but said it is waiting for more information from Britain’s Medicines and Healthcare products Regulatory Agency (MHRA).
The MHRA is one of many bodies across the globe analysing real world data from the AstraZeneca rollout to see if there is a definitive link between the jab and a rare form of blood clot, after cases were initially reported in Norway and continental Europe.
The MHRA reported over the weekend that there had been 30 blood clotting cases, seven fatal, out of the 18 million doses administered in Britain.
It is the latest drama to hit AstraZeneca, which has been involved in controversy over its failure to deliver promised doses to the European Union, and over the jab’s efficacy and safety profile.
The European Medicines Agency said Tuesday it “has not yet reached a conclusion and the review is currently ongoing”.
Also, EU Health Commissioner Stella Kyriakides later said that the agency was expected to make its decision late Wednesday, adding that she was in close contact with the EMA.
Discover more from LN247
Subscribe to get the latest posts sent to your email.
